Axsome Therapeutics (AXSM) Cost of Revenue (2022 - 2026)

Axsome Therapeutics' Cost of Revenue history runs 5 years deep, the most recent figure standing at $14.7 million for Q1 2026.

• In Q1 2026, Cost of Revenue rose 50.42% year-over-year to $14.7 million; the TTM figure through Mar 2026 stood at $52.4 million (up 42.45% YoY), while the FY2025 annual figure was $47.5 million, up 42.56% from the prior year.
• Cost of Revenue came in at $14.7 million for Q1 2026 at Axsome Therapeutics, up from $12.3 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $14.7 million in Q1 2026 to a low of $983000.0 in Q2 2022.
• A 5-year average of $7.9 million and a median of $7.8 million in 2023 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue jumped 367.85% in 2023 and fell 16.66% in 2024, its largest moves.
• Axsome Therapeutics' Cost of Revenue stood at $2.3 million in 2022, then soared by 222.04% to $7.4 million in 2023, then surged by 42.5% to $10.5 million in 2024, then gained by 17.26% to $12.3 million in 2025, then climbed by 19.43% to $14.7 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $14.7 million, $12.3 million, and $11.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison